Seagen, Astellas Pharma Report Positive Topline Results From EV-302 Trial

(RTTNews) - Seagen Inc. (SGEN) and Astellas Pharma Inc. reported positive topline results from the Phase 3 EV-302 trial for PADCEV in combination with KEYTRUDA versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer. The company said the EV-302 study met dual primary endpoints of overall survival and progression-free survival, compared to chemotherapy.

The company noted that EV-302 trial is intended to serve as the basis for global submissions and as the confirmatory trial for the U.S. accelerated approval of this combination.

For More Such Health News, visit rttnews.com.